Abituzumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Abituzumab

Accession Number

DB12775

Description

Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.

Type

Biotech

Groups

Investigational

Biologic Classification

Protein Based Therapies
Monoclonal antibody (mAb)

Protein Chemical Formula

Not Available

Protein Average Weight

Not Available

Sequences

Not Available

Synonyms

Not Available

External IDs

Emd 525797

Pharmacology

Indication: Not Available
Contraindications & Blackbox Warnings: Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Learn about our commercial Adverse Effects data.
Learn More
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Abituzumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Abituzumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abituzumab.
Alirocumab	The risk or severity of adverse effects can be increased when Alirocumab is combined with Abituzumab.
Ansuvimab	The risk or severity of adverse effects can be increased when Abituzumab is combined with Ansuvimab.
Anthrax immune globulin human	The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Abituzumab.
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Abituzumab.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abituzumab.
Asfotase alfa	The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Abituzumab.
Atezolizumab	The risk or severity of adverse effects can be increased when Atezolizumab is combined with Abituzumab.

Additional Data Available

Extended Description

Available for Purchase

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

Available for Purchase

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

Available for Purchase

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

Available for Purchase

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

Chemical Identifiers

UNII: 724QD330RD
CAS number: 1105038-73-0

References

General References

Not Available

External Links

PubChem Substance: 347911378
Wikipedia: Abituzumab

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Metastatic Hormone Refractory Prostate Cancer	1
2	Terminated	Treatment	Systemic Sclerosis-associated Interstitial Lung Disease	1
2	Withdrawn	Treatment	Metastatic Colorectal Cancer (MCRC)	1
1	Completed	Treatment	Bone Metastases / Prostate Cancer	1
1	Completed	Treatment	Colorectal and Ovarian Cancer Patients With Liver Metastases	1
1	Completed	Treatment	Tumors, Solid	1
1, 2	Completed	Treatment	Metastatic Colorectal Cancer (MCRC)	1